Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37955 | 0.79 | TSHR (0.45) | TDP2NSD2HSP90AA1PAX8TSHR | |
| SCHEMBL5494672 | 0.79 | TSHR (0.45) | TDP2NSD2HSP90AA1PAX8TSHR | |
| SCHEMBL5181689 | 0.75 | TSHR (0.43) | TDP2NSD2HSP90AA1PAX8TSHR | |
| SCHEMBL10346182 | 0.75 | TSHR (0.43) | TDP2NSD2HSP90AA1PAX8TSHR | |
| SCHEMBL571577 | 0.75 | TSHR (0.43) | TDP2NSD2HSP90AA1PAX8TSHR | |
| SCHEMBL9720717 | 0.75 | TDP2 (0.31) | TDP2NSD2HSP90AA1PAX8 | |
| SCHEMBL11321097 | 0.75 | TDP2 (0.36) | TDP2NSD2HSP90AA1PAX8TSHR | |
| SCHEMBL17065147 | 0.75 | TDP2 (0.36) | TDP2NSD2HSP90AA1PAX8TSHR | |
| SCHEMBL50045 | 0.73 | — | — | |
| SCHEMBL394771 | 0.71 | TDP2 (0.42) | TDP2NSD2HSP90AA1PAX8TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 753 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117831652-A | Prediction method of olefin hydroformylation positive-to-negative ratio | 上海华谊控股集团有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-116410239-A | Heteroatom-containing metallocene compound and preparation method and application thereof | 惠生(中国)投资有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-110818545-B | Method for preparing substituted aryl ketone by ketone arylation | 上海化工研究院有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-110922286-B | Asymmetric aryl substituted fulvene compound and preparation method and application thereof | 上海化工研究院有限公司 | 2022-08-16 | — | — | CN | claimed |
| CN-107963982-B | Polyisocyanate composition and isocyanate polymer composition | 旭化成株式会社 | 2021-11-12 | — | — | CN | claimed |
| US-10745372-B2 | Compound, resin, material for forming underlayer film for lithography, underlayer film for lithography, pattern forming method, and purification method | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2020-08-18 | — | — | US | claimed |
| CN-110922286-A | Asymmetric aryl substituted fulvene compound and preparation method and application thereof | 上海化工研究院有限公司 | 2020-03-27 | — | — | CN | claimed |
| CN-110818545-A | Method for preparing substituted aryl ketone by ketone arylation | 上海化工研究院有限公司 | 2020-02-21 | — | — | CN | claimed |
| EP-1363955-B1 | MULTINUCLEAR METALLOCENE CATALYST | HONAM PETROCHEMICAL CORP (KR) | 2008-04-09 | — | — | EP | claimed |
| US-6943225-B2 | Multinuclear metallocene catalyst | HONAM PETROCHEMICAL CORPORATION (KR) | 2005-09-13 | — | — | US | claimed |
| WO-2004076502-A1 | SUPPORTED MULTINUCLEAR METALLOCENE CATALYST FOR OLEFIN POLYMERIZATION AND METHOD FOR PREPARING THE SAME | HONAM PETROCHEMICAL CORPORATION (KR) | 2004-09-10 | — | — | WO | claimed |
| US-20040072677-A1 | Multinuclear metallocene catalyst | HONAM PETROCHEMICAL CORPORATION (KR) | 2004-04-15 | — | — | US | claimed |
| EP-1363955-A1 | MULTINUCLEAR METALLOCENE CATALYST | Honam Petrochemical Corporation (KR) | 2003-11-26 | — | — | EP | claimed |
| WO-2002060964-A1 | MULTINUCLEAR METALLOCENE CATALYST | HONAM PETROCHEMICAL CORPORATION (KR) | 2002-08-08 | — | — | WO | claimed |
| US-5674856-A | TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS, INCLUDING AIDS AND TUMORS | SANKYO COMPANY, LIMITED (JP) | 1997-10-07 | — | — | US | claimed |
| EP-0611075-B1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1996-12-18 | — | — | EP | claimed |
| EP-0611075-A1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-08-17 | — | — | EP | claimed |
| CN-118302407-A | Carbonyl compound, method for producing isocyanate compound, and isocyanate composition | 旭化成株式会社 | 2024-07-05 | — | — | CN | disclosed |
| US-4300942-A | N-(Substituted carbonyl) derivatives of N-phos-phinylmethylglycinates and the herbicidal use thereof | MONSANTO COMPANY (US) | 1981-11-17 | — | — | US | disclosed |
| US-4251258-A | N-(Substituted carbonyl) derivatives of N-phosphinylmethylglycinates and the herbicidal use thereof | MONSANTO COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745372-B2 | Compound, resin, material for forming underlayer film for lithography, underlayer film for lithography, pattern forming method, and purification method | ASH2L, MLLT1, FRG1 | TDP2 3895/4885NSD2 756/4885HSP90AA1 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.